Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on February 3, 2005

Stroke. 2005
Published online before print February 3, 2005, doi: 10.1161/01.STR.0000155738.02753.4d
A more recent version of this article appeared on March 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/3/e17    most recent
01.STR.0000155738.02753.4dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolff, V.
Right arrow Articles by Lanza, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolff, V.
Right arrow Articles by Lanza, F.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Stroke
*Transient Ischemic Attack
Related Collections
Right arrow Arterial thrombosis
Right arrow Coagulation
Right arrow Thrombin
Right arrow Acute Stroke Syndromes
Right arrow Anticoagulants
Right arrow Antiplatelets
Right arrow Platelets

Submitted on September 6, 2004
Revised on November 15, 2004
Accepted on November 30, 2004

Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke

Valérie Wolff MD; Boris Aleil MD, PhD; Maurice Giroud MD; Jean-Louis Lorenzini MD; Nicolas Meyer MD; Marie-Louise Wiesel MD; Jean-Pierre Cazenave MD, PhD; and François Lanza PharmD, PhD*

From the Etablissement Français du Sang--Alsace (V.W., B.A., M.-L.W., J.-P.C., F.L.), Institut National de la Santé et de la Recherche Médicale U.311, Strasbourg, France; Service de Neurologie (V.W.), Hôpital Civil, Strasbourg, France; Service de Neurologie (M.G.), Centre Hospitalier Universitaire, Dijon, France; Laboratoire d’Hématologie (J.-L.L.), Hôpital du Bocage, Dijon, France; and Département de Santé Publique (N.M.), Hôpital Civil, Strasbourg, France.

* To whom correspondence should be addressed. E-mail: francois.lanza{at}efs-alsace.fr.

Background and Purpose--The diagnosis and management of patients with acute ischemic stroke still lack an informative biochemical test. Soluble glycoprotein V (sGPV) is a new plasmatic marker of thrombosis released from the platelet surface by thrombin. The objective of this prospective study was to compare the levels of sGPV in stroke and control patients.

Methods--Consecutive patients with acute ischemic stroke (n=159) and controls (n=70) were recruited for sGPV measurement.

Results--Plasmatic levels of sGPV were significantly increased in ischemic stroke compared with control patients (median [interquartile range] 39.4 [31.8 to 52.9] versus 28.1 [24.0 to 37.9] ng/mL; P<0.0001). In multivariate analysis, ischemic stroke was the major determinant of the sGPV increase (odds ratio [95% CI], 5.87 [2.62 to 13.12]; P<0.0001).

Conclusions--sGPV is a new marker of arterial thrombosis and represents a tool to study the mechanisms involved in ischemic stroke. The increase in plasmatic sGPV observed in stroke patients supports a role of platelets and thrombin in the events leading to ischemic stroke.
Key words: platelets • stroke • thrombosis






Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.